Cerespir Announces Chris Griffett Will Serve As Vice President, Regulatory Affairs
Published: Jan 10, 2014
NEW YORK, Jan. 10, 2014 (GLOBE NEWSWIRE) -- CereSpir™ Incorporated, a company developing CHF 5074, a first-in-class microglial modulator as a potential treatment for Alzheimer's disease, today announced Chris Griffett, BSc (Hons), C.Biol., FTOPRA, will serve as the Company's Vice President, Regulatory Affairs. Mr. Griffett will report directly to Daniel G. Chain, PhD, Chairman, President and Chief Executive Officer of CereSpir.
Help employers find you! Check out all the jobs and post your resume.